Aligos Therapeutics, Inc. delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-ß) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 ? 7, 2023. Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg: Key Highlights: Oral dosing with 300 mg of ALG-000184 ± entecavir (ETV) for up to 48 weeks in untreated HBeAg positive chronic hepatitis B patients demonstrated a favorable safety profile and greater suppression of HBV DNA and RNA versus ETV alone; No viral breakthroughs occurred when ALG-000184 was given as a monotherapy for up to 44 weeks; Dose dependent, multi-log reductions were seen in HBsAg, HBeAg and HBcrAg; ALG-000184 appeared to lower cccDNA levels via 1st and 2nd mechanisms of action of CAM-E drugs and ALG-000184 may play an important role in enhancing rates of chronic suppression and/or functional cure in CHB patients.

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, in Hyperlipidaemic Subjects and Relative Bioavailability/Food Effect of a Solid Formulation in Healthy Volunteers: Key Highlights: In the Phase 1 study, ALG-055009 was well tolerated with a favorable PK profile that is differentiated from VK-2809 and resmetirom; Expected thyromimetic effects were observed: dose-dependent increases in sex hormone binding globulin levels (SHBG) and decreases in lipid levels; No food effect using Phase 2a gel cap formulation in healthy volunteers and Demonstrates best-in-class properties as a THR-ß agonist.